Epidemiology of hepatocellular carcinoma in USA. Hepatol. Res. 2007; 37: S88–94. .
Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004; 127 (5 Suppl. 1): S35–50. , , , .
et al. Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol. Res. 2008; 38: 37–51. , ,
Management of hepatocellular carcinoma in Japan: consensus-based clinical practice manual proposed by the Japan Society of Hepatology. Oncology 2007; 72: S2–15. , .
Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208–36. , .
et al. Report of the 17th nationwide follow-up survey of primary liver cancer in Japan. Hepatol. Res. 2007; 37: 676–91. , ,
et al. Screening in liver disease: report of an AASLD clinical workshop. Hepatology 2004; 39: 1204–12. , ,
et al. Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review. Hepatology 2002; 36 (5 Suppl. 1): S84–92. , ,
et al. Evaluation of curability and prediction of prognosis after surgical treatment for hepatocellular carcinoma by lens culinaris agglutinin-reactive alpha-fetoprotein. Int. J. Oncol. 1999; 14: 265–71. , ,
et al. Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer 2001; 91: 561–9. , ,
AASLD single-topic research conference on hepatocellular carcinoma: Conference proceedings. Hepatology 2004; 40: 1465–73. , .
et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003; 125: 89–97. , ,
et al. Serum human telomerase reverse transcriptase messenger RNA as a novel tumor marker for hepatocellular carcinoma. Clin. Cancer Res. 2005; 11: 3205–9. , ,
et al. Characterization of hepatic tumors: value of contrast-enhanced coded phase-inversion harmonic angio. AJR Am. J. Roentgenol. 2004; 182: 1019–26. , ,
Hepatocellular carcinoma: depiction of tumor parenchymal flow with intermittent harmonic power Doppler US during the early arterial phase in dual-display mode. Radiology 2001; 220: 349–56. , , , , , .
et al. Differential diagnosis of nodular lesions in cirrhotic liver by post-vascular phase contrast-enhanced US with Levovist: comparison with superparamagnetic iron oxide magnetic resonance images. J. Gastroenterol. 2005; 40: 1139–47. , ,
Contrast-enhanced subtraction harmonic sonography for evaluating treatment response in patients with hepatocellular carcinoma. AJR Am. J. Roentgenol. 2001; 176: 661–6. , , , , , .
et al. Transcatheter arterial chemoembolization of hepatocellular carcinoma: usefulness of coded phase-inversion harmonic sonography. AJR Am. J. Roentgenol. 2003; 180: 703–8. , ,
et al. Evaluation of posttreatment response of hepatocellular carcinoma with contrast-enhanced coded phase-inversion harmonic US: comparison with dynamic CT. Radiology 2001; 221: 721–30. , ,
Treatment of hepatocellular carcinoma with percutaneous radiofrequency ablation: usefulness of contrast harmonic sonography for lesions poorly defined with B-mode sonography. AJR Am. J. Roentgenol. 2004; 183: 153–6. , , , , , .
et al. Contrast harmonic sonography-guided radiofrequency ablation therapy versus B-mode sonography in hepatocellular carcinoma: prospective randomized controlled trial. AJR Am. J. Roentgenol. 2007; 188: 489–94. , ,
et al. Radiofrequency ablation of hepatocellular carcinoma: therapeutic response using contrast-enhanced coded phase-inversion harmonic sonography. AJR Am. J. Roentgenol. 2003; 181: 57–63. , ,
et al. Imaging of hepatocellular carcinoma: Qualitative and quantitative analysis of postvascular phase contrast-enhanced ultrasonography with Sonazoid. Oncology. 2008; 75 (Suppl. 1): 48–54. , ,
Defect reperfusion imaging, a newly developed novel technology using Sonazoid in the treatment of hepatocellular carcinoma. J. Med. Ultrasound. 2008; 16: 169–75. , , .
A proposal of novel treatment-assist technique for hepatocellular carcinoma in the Sonazoid-enhanced ultrasonography: value of defect re-perfusion imaging. Kanzo. 2007; 48: 299–301. (In Japanese.), , , , .
Sonazoid-enhanced ultrasound in the diagnosis and treatment of hepatic tumors. J. Med. Ultrasound. 2008; 16: 130–9. , , .
Sonazoid-enhanced ultrasonography for diagnosis of hepatic malignancies: comparison with contrast-enhanced CT. Oncology 2008; 75 (Suppl. 1): 42–7. , , , .
et al. Response evaluation of transcatheter arterial chemoembolization in hepatocellular carcinomas: The usefulness of Sonazoid-enhanced harmonic sonography. Oncology. 2008; 75 (Suppl. 1): 99–105. , ,
Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by the organic anion transporting polypeptide Oatp1. J. Pharmacol. Exp. Ther. 1999; 290: 153–7. , , , , , .
et al. Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J. Gastroenterol. 2009; 44: 793–8. , ,
et al. Abc protein transport of MRI contrast agents in canalicular rat liver plasma vesicles and yeast vacuoles. Biochem. Biophys. Res. Commun. 2001; 282: 60–6. , ,
Magnetic resonance imaging of hepatocellular carcinoma. Oncology 2008; 75 (Suppl. 1): 65–71. , , , , .
Magnetic resonance imaging of hepatocellular carcinoma using contrast media. Oncology. 2008; 75 (Suppl. 1): 72–82. , , , .
Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 2009; 49: 658–64. , , .
et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J. Hepatol. 2001; 35: 421–30. , ,
Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin. Liver. Dis. 1999; 19: 329–38. , , .
The Cancer of the Liver Italian Program (CLIP) Investigators. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 2000; 31: 810–45.
Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J. Gastroenterol. 2003; 38: 207–15. , , .
et al. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology 2004; 40: 1396–405. , ,
et al. Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients. Gut 2005; 54: 419–25. , ,
Liver Cancer Study Group of Japan. General Rules for the Clinical and Pathological Study of Primary Liver Cancer. English ed 2. Tokyo: Kanehara, 2003.
et al. A modified Japan Integrated Stage score for prognostic assessment in patients with hepatocellular carcinoma. J. Gastroenterol. 2006; 41: 884–92. , ,
et al. Staging hepatocellular carcinoma by a novel scoring system (BALAD score) based on serum markers. Clin. Gastroenterol. Hepatol. 2006; 4: 1528–36. , ,
et al. Validation of a new prognostic staging system for hepatocellular carcinoma: A comprison of the biomarker-combined Japan integrated staging score, the conventional Japan integrated staging score and the BALAD score. Oncology. 2008; 75 (Suppl. 1): 83–90. , ,
et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer 2002; 95: 588–95. , ,
et al. Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 2002; 94: 435–42. , ,
et al. Combination therapy with S-1 and pegylated interferon alpha for advanced hepatocellular carcinoma. Oncology. 2008; 75 (Suppl. 1): 106–13. , ,
et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008; 359: 378–90. , ,
et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009; 10: 25–34. , ,
Japan Society of Hepatology: Management of hepatocellular carcinoma in Japan: consensus-based clinical practice manual proposed by the Japan Society of Hepatolgy. Oncology 2007; 72: S2–15. , .
Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted therapy. Oncology 2008; 75: S1–12. .
Impact of interferon therapy after curative treatment of hepatocellular carcinoma. Oncology 2008; 75 (Suppl. 1): 30–41. .